EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs
Exenatide, Non-GLP-1 RA based glucose lowering drugs
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: -
Verified 01 Sept 2023 by AstraZeneca
No locations available
|Initiators of exenatide|
Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide during the study period, 2006 to 2023
All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
Other Name: BYETTA, BYDUREON/BYDUREON BCise
|Initiators of non-GLP-1 RA based glucose lowering drugs|
Patients with T2DM, aged 18 years or older, who initiated treatment with non-GLP-1 RA based glucose lowering drugs during the study period, 2006 to 2023
Drug: Non-GLP-1 RA based glucose lowering drugs
Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
Other Name: Insulin/analogues (excl. A10AE54, A10A56), Biguanide, Sulfonylurea, Sulfonamide (heterocycl.), combined oral GLD (excl. DPP-4i), Alpha glucose inhib., Thiazolidinedione, SGLT2i, Oth. GLD excl. insulin